Drug Profile
Research programme: metabolic disorder therapeutics - Energesis Pharmaceuticals
Alternative Names: Brown adipose tissue stimulants - Energesis Pharmaceuticals; Brown fat stimulants - Energesis Pharmaceuticals; Brown fat-based therapeutics - Energesis PharmaceuticalsLatest Information Update: 10 Oct 2023
Price :
$50
*
At a glance
- Originator Energesis Pharmaceuticals
- Developer Energesis Pharmaceuticals; Johnson & Johnson Innovative Medicine
- Class
- Mechanism of Action Cell division stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Metabolic disorders
Most Recent Events
- 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)
- 04 Nov 2017 No recent reports of development identified for research development in Metabolic-disorders in USA
- 01 May 2014 Energesis Pharmaceuticals receives Phase I SBIR grant from National Institutes of Health for Metabolic disorder therapeutics